149 related articles for article (PubMed ID: 31079160)
21. Use of Physiologically-Based Kinetics Modelling to Reliably Predict Internal Concentrations of the UV Filter, Homosalate, After Repeated Oral and Topical Application.
Najjar A; Schepky A; Krueger CT; Dent M; Cable S; Li H; Grégoire S; Roussel L; Noel-Voisin A; Hewitt NJ; Cardamone E
Front Pharmacol; 2021; 12():802514. PubMed ID: 35058784
[TBL] [Abstract][Full Text] [Related]
22. Hepatic Organic Anion Transporting Polypeptide-Mediated Clearance in the Beagle Dog: Assessing In Vitro-In Vivo Relationships and Applying Cross-Species Empirical Scaling Factors to Improve Prediction of Human Clearance.
Matsunaga N; Ufuk A; Morse BL; Bedwell DW; Bao J; Mohutsky MA; Hillgren KM; Hall SD; Houston JB; Galetin A
Drug Metab Dispos; 2019 Mar; 47(3):215-226. PubMed ID: 30593544
[TBL] [Abstract][Full Text] [Related]
23. Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors.
Lee CK; Choi JS; Choi DH
Pharmacol Rep; 2015 Feb; 67(1):44-51. PubMed ID: 25560574
[TBL] [Abstract][Full Text] [Related]
24. Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data.
Jones HM; Barton HA; Lai Y; Bi YA; Kimoto E; Kempshall S; Tate SC; El-Kattan A; Houston JB; Galetin A; Fenner KS
Drug Metab Dispos; 2012 May; 40(5):1007-17. PubMed ID: 22344703
[TBL] [Abstract][Full Text] [Related]
25. Predicting Human Clearance of Organic Anion Transporting Polypeptide Substrates Using Cynomolgus Monkey: In Vitro-In Vivo Scaling of Hepatic Uptake Clearance.
De Bruyn T; Ufuk A; Cantrill C; Kosa RE; Bi YA; Niosi M; Modi S; Rodrigues AD; Tremaine LM; Varma MVS; Galetin A; Houston JB
Drug Metab Dispos; 2018 Jul; 46(7):989-1000. PubMed ID: 29720472
[TBL] [Abstract][Full Text] [Related]
26. Towards best use and regulatory acceptance of generic physiologically based kinetic (PBK) models for in vitro-to-in vivo extrapolation (IVIVE) in chemical risk assessment.
Najjar A; Punt A; Wambaugh J; Paini A; Ellison C; Fragki S; Bianchi E; Zhang F; Westerhout J; Mueller D; Li H; Shi Q; Gant TW; Botham P; Bars R; Piersma A; van Ravenzwaay B; Kramer NI
Arch Toxicol; 2022 Dec; 96(12):3407-3419. PubMed ID: 36063173
[TBL] [Abstract][Full Text] [Related]
27. Organic Anion-Transporting Polypeptide (OATP)-Mediated Drug-Drug Interaction Study between Rosuvastatin and Cyclosporine A in Chimeric Mice with Humanized Liver.
Uchida M; Tajima Y; Kakuni M; Kageyama Y; Okada T; Sakurada E; Tateno C; Hayashi R
Drug Metab Dispos; 2018 Jan; 46(1):11-19. PubMed ID: 29051147
[TBL] [Abstract][Full Text] [Related]
28. In Vitro-In Vivo Extrapolation Scaling Factors for Intestinal P-glycoprotein and Breast Cancer Resistance Protein: Part II. The Impact of Cross-Laboratory Variations of Intestinal Transporter Relative Expression Factors on Predicted Drug Disposition.
Harwood MD; Achour B; Neuhoff S; Russell MR; Carlson G; Warhurst G; Rostami-Hodjegan A
Drug Metab Dispos; 2016 Mar; 44(3):476-80. PubMed ID: 26842595
[TBL] [Abstract][Full Text] [Related]
29. Mechanistic modeling of hepatic transport from cells to whole body: application to napsagatran and fexofenadine.
Poirier A; Funk C; Scherrmann JM; Lavé T
Mol Pharm; 2009; 6(6):1716-33. PubMed ID: 19739673
[TBL] [Abstract][Full Text] [Related]
30. Metabolic stability and uptake by human hepatocytes of pitavastatin, a new inhibitor of HMG-CoA reductase.
Fujino H; Nakai D; Nakagomi R; Saito M; Tokui T; Kojima J
Arzneimittelforschung; 2004; 54(7):382-8. PubMed ID: 15344842
[TBL] [Abstract][Full Text] [Related]
31. Clinical pharmacokinetics of fluvastatin.
Scripture CD; Pieper JA
Clin Pharmacokinet; 2001; 40(4):263-81. PubMed ID: 11368292
[TBL] [Abstract][Full Text] [Related]
32. Regional intestinal absorption and biliary excretion of fluvastatin in the rat: possible involvement of mrp2.
Lindahl A; Sjöberg A; Bredberg U; Toreson H; Ungell AL; Lennernäs H
Mol Pharm; 2004; 1(5):347-56. PubMed ID: 16026004
[TBL] [Abstract][Full Text] [Related]
33. Comparison of the Predictability of Human Hepatic Clearance for Organic Anion Transporting Polypeptide Substrate Drugs Between Different In Vitro-In Vivo Extrapolation Approaches.
Izumi S; Nozaki Y; Komori T; Takenaka O; Maeda K; Kusuhara H; Sugiyama Y
J Pharm Sci; 2017 Sep; 106(9):2678-2687. PubMed ID: 28238896
[TBL] [Abstract][Full Text] [Related]
34. Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors.
Fujino H; Saito T; Tsunenari Y; Kojima J; Sakaeda T
Xenobiotica; 2004; 34(11-12):961-71. PubMed ID: 15801541
[TBL] [Abstract][Full Text] [Related]
35. Rosuvastatin Liver Partitioning in Cynomolgus Monkeys: Measurement In Vivo and Prediction Using In Vitro Monkey Hepatocyte Uptake.
Morse BL; Cai H; MacGuire JG; Fox M; Zhang L; Zhang Y; Gu X; Shen H; Dierks EA; Su H; Luk CE; Marathe P; Shu YZ; Humphreys WG; Lai Y
Drug Metab Dispos; 2015 Nov; 43(11):1788-94. PubMed ID: 26341276
[TBL] [Abstract][Full Text] [Related]
36. Model-based approaches to predict drug-drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond.
Barton HA; Lai Y; Goosen TC; Jones HM; El-Kattan AF; Gosset JR; Lin J; Varma MV
Expert Opin Drug Metab Toxicol; 2013 Apr; 9(4):459-72. PubMed ID: 23331046
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions.
Shitara Y; Sugiyama Y
Pharmacol Ther; 2006 Oct; 112(1):71-105. PubMed ID: 16714062
[TBL] [Abstract][Full Text] [Related]
38. Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration-Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics.
Song L; Zhang Y; Jiang J; Ren S; Chen L; Liu D; Chen X; Hu P
Clin Pharmacokinet; 2018 Oct; 57(10):1307-1323. PubMed ID: 29626326
[TBL] [Abstract][Full Text] [Related]
39. Drug-drug interaction between pitavastatin and various drugs via OATP1B1.
Hirano M; Maeda K; Shitara Y; Sugiyama Y
Drug Metab Dispos; 2006 Jul; 34(7):1229-36. PubMed ID: 16595711
[TBL] [Abstract][Full Text] [Related]
40. Importance of in vitro conditions for modeling the in vivo dose in humans by in vitro-in vivo extrapolation (IVIVE).
Algharably EAH; Kreutz R; Gundert-Remy U
Arch Toxicol; 2019 Mar; 93(3):615-621. PubMed ID: 30604139
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
